Related Experiment Video
Updated: Aug 7, 2026
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
[Heart transplant in "Nuevo Leon": the first 33 cases]
Eduardo Herrera Garza1, Julio Molina Gamboa, Horacio Decanini Arcaute
1IMSS Monterrey, Hospital San José TEC de Monterrey. eduardoherrera@intercable.net
Insights
Heart transplantation offers a life-saving option for end-stage heart failure patients. This study highlights successful outcomes, including advanced age and novel device use, achieving an 82% one-year survival rate comparable to global standards.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunosuppression Therapy
Context:
- Heart failure is a leading global cause of mortality.
- Heart transplantation is a critical treatment for end-stage heart failure when other therapies fail.
- Immunosuppressive therapy post-transplant can lead to complications like graft rejection and infections.
Purpose:
- To report the experience and outcomes of 33 heart transplant patients.
- To highlight the program's success in transplanting elderly patients.
- To document the first use of the ambulatory Thoratec TLC II system for heart transplant assistance in Latin America.
Summary:
- The study details the outcomes of 33 heart transplant recipients.
- The program successfully performed transplants on elderly patients and utilized the Thoratec TLC II system.
- Despite resource limitations, complications were managed effectively, mirroring those in other programs.
Impact:
- Achieved an 82% one-year survival rate, comparable to established international benchmarks.
- Demonstrated the feasibility of advanced heart transplantation techniques in Latin America.
- Provides valuable insights into managing heart transplant complications in resource-constrained settings.
Abstract:
Heart failure is one of the most important causes of death worldwide. Heart transplant is the last effective alternative when the medical and surgical treatments have failed in patients with end stage heart failure, giving them an 80% one year survival rate. Unfortunately, during the outcome, the heart transplant patients can develop complications such as graft rejection and opportunistic infections because of the use of immunosuppressive therapy. In the present article we report the experience with 33 heart transplant patients. Our program not only has successfully transplanted patients with advanced age but, for the first time in Latin America we have transplanted patients assisted with the ambulatory Thoratec TLC II system. Even with limited resources, we have managed the same complications than other heart transplant programs, our 82% one year survival rate is similar than reports in medical literature.
More Related Videos
09:54Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
07:08A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
Published on: June 6, 2025
